REGENT PHARMACIES LIMITED Filleted accounts for Companies House (small and micro)

COMPANY REGISTRATION NUMBER: 03621682

REGENT PHARMACIES LIMITED

Filleted Unaudited Financial Statements

For the year ended

30 November 2025

REGENT PHARMACIES LIMITED

Financial Statements

Year ended 30 November 2025

Contents	Pages

Statement of financial position	1 to 2

Notes to the financial statements	3 to 9

REGENT PHARMACIES LIMITED

Statement of Financial Position

30 November 2025

	2025		2024
Note	£	£	£

Fixed assets

Tangible assets	6		45,703	63,476

Current assets

Stocks		31,179	36,519
Debtors	7	137,874	177,980
Cash at bank and in hand		14,489	22,194
		---------	---------
		183,542	236,693

Creditors: amounts falling due within one year	8	( 230,527)		( 225,694)
		---------		---------
Net current (liabilities)/assets			( 46,985)	10,999
			--------	--------
Total assets less current liabilities			( 1,282)	74,475

Creditors: amounts falling due after more than one year	9		( 7,782)	( 28,852)

Provisions

Taxation including deferred tax	( 8,100)	( 15,041)
	--------	--------
Net (liabilities)/assets	( 17,164)	30,582
	--------	--------

Capital and reserves

Called up share capital	10	100	100
Profit and loss account		( 17,264)	30,482
		--------	--------
Shareholders (deficit)/funds		( 17,164)	30,582
		--------	--------

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.

In accordance with section 444 of the Companies Act 2006, the statement of income and retained earnings has not been delivered.

For the year ending 30 November 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476 ;

- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements .

REGENT PHARMACIES LIMITED

Statement of Financial Position (continued)

30 November 2025

These financial statements were approved by the board of directors and authorised for issue on 26 August 2026 , and are signed on behalf of the board by:

S K KOCHHAR
Director

Company registration number: 03621682

REGENT PHARMACIES LIMITED

Notes to the Financial Statements

Year ended 30 November 2025

1. General information

The company is a private company limited by shares, registered in England and Wales. The address of the registered office is 19-20 Windmill Street, Gravesend, Kent, DA12 1AS.

2. Statement of compliance

These financial statements have been prepared in compliance with Section 1A of FRS 102, 'The Financial Reporting Standard applicable in the UK and the Republic of Ireland'.

3. Accounting policies

(a) Basis of preparation

The financial statements have been prepared on the historical cost basis. The financial statements are prepared in UK sterling, which is the functional currency of the entity. Monetary amounts in these financial statements are rounded to the nearest UK pound.

(b) Trade receivable

Trade receivables do not carry any interest and are stated at their original invoice value as reduced by appropriate allowances for estimated irrecoverable amounts.

(c) Going concern

The financial statements have been prepared on a going concern basis. The company is dependant on the continued support of its director who has given confirmation that he does not intend to withdraw such support in the foreseeable future. The financial statements do not include any adjustments whwich might result from a withdrawal of such support.

(d) Trade payable

Trade payables do not carry any interest and are stated at their original invoice value.

(e) Revenue recognition

Turnover is measured at the fair value of the consideration received or receivable for goods supplied and services rendered, net of discounts and Value Added Tax. Revenue from the sale of goods is recognised when the significant risks and rewards of ownership have transferred to the buyer (usually on despatch of the goods); the amount of revenue can be measured reliably; it is probable that the associated economic benefits will flow to the entity; and the costs incurred or to be incurred in respect of the transactions can be measured reliably.

(f) Income tax

The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in profit or loss, except to the extent that it relates to items recognised in other comprehensive income. In this case, tax is recognised in other comprehensive income. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date. Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.

(g) Operating leases

Lease payments are recognised as an expense over the lease term on a straight-line basis. The aggregate benefit of lease incentives is recognised as a reduction to expense over the lease term, on a straight-line basis.

(h) Goodwill

Goodwill arises on business acquisitions and represents the excess of the cost of the acquisition over the company's interest in the net amount of the identifiable assets, liabilities and contingent liabilities of the acquired business. Goodwill is measured at cost less accumulated amortisation and accumulated impairment losses. It is amortised on a straight-line basis over its useful life. Where a reliable estimate of the useful life of goodwill or intangible assets cannot be made, the life is presumed not to exceed ten years.

(i) Amortisation

Amortisation is calculated so as to write off the cost of an asset, less its estimated residual value, over the useful life of that asset as follows:

	Goodwill	-	20 years

If there is an indication that there has been a significant change in amortisation rate, useful life or residual value of an intangible asset, the amortisation is revised prospectively to reflect the new estimates.

(j) Tangible assets

Tangible assets are initially recorded at cost, and subsequently stated at cost less any accumulated depreciation and impairment losses.

(k) Depreciation

Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

Leasehold property	-	Over lease period of 15 and 20 years
Plant & machinery	-	Over 5 years
Fixtures & fittings	-	Over 5 years
Motor vehicles	-	Over 5 years

(l) Impairment of fixed assets

A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly.

(m) Stocks

Stocks are measured at the lower of cost and estimated selling price less costs to complete and sell. Cost includes all costs of purchase, costs of conversion and other costs incurred in bringing the stock to its present location and condition.

(n) Finance leases and hire purchase contracts

Assets held under finance leases and hire purchase contracts are recognised in the statement of financial position as assets and liabilities at the lower of the fair value of the assets and the present value of the minimum lease payments, which is determined at the inception of the lease term. Any initial direct costs of the lease are added to the amount recognised as an asset. Lease payments are apportioned between the finance charges and reduction of the outstanding lease liability using the effective interest method. Finance charges are allocated to each period so as to produce a constant rate of interest on the remaining balance of the liability.

(o) Provisions

Provisions are recognised when the entity has an obligation at the reporting date as a result of a past event, it is probable that the entity will be required to transfer economic benefits in settlement and the amount of the obligation can be estimated reliably. Provisions are recognised as a liability in the statement of financial position and the amount of the provision as an expense. Provisions are initially measured at the best estimate of the amount required to settle the obligation at the reporting date and subsequently reviewed at each reporting date and adjusted to reflect the current best estimate of the amount that would be required to settle the obligation. Any adjustments to the amounts previously recognised are recognised in profit or loss unless the provision was originally recognised as part of the cost of an asset.

(p) Defined contribution plans

Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised as a finance cost in profit or loss in the period in which it arises.

4. Employee numbers

The average number of persons employed by the company during the year amounted to 10 (2024: 10 ).

5. Intangible assets

	Goodwill
	£
Cost
At 1 December 2024 and 30 November 2025	180,000
	---------
Amortisation
At 1 December 2024 and 30 November 2025	180,000
	---------
Carrying amount
At 30 November 2025	–
	---------
At 30 November 2024	–
	---------

6. Tangible assets

	Land and buildings	Plant and machinery	Fixtures, fittings and equipment	Motor vehicles	Total
	£	£	£	£	£
Cost
At 1 December 2024	8,009	38,974	71,755	49,235	167,973
Additions	–	–	2,875	–	2,875
	-------	--------	--------	--------	---------
At 30 November 2025	8,009	38,974	74,630	49,235	170,848
	-------	--------	--------	--------	---------
Depreciation
At 1 December 2024	5,129	38,974	43,982	16,412	104,497
Charge for the year	159	–	10,642	9,847	20,648
	-------	--------	--------	--------	---------
At 30 November 2025	5,288	38,974	54,624	26,259	125,145
	-------	--------	--------	--------	---------
Carrying amount
At 30 November 2025	2,721	–	20,006	22,976	45,703
	-------	--------	--------	--------	---------
At 30 November 2024	2,880	–	27,773	32,823	63,476
	-------	--------	--------	--------	---------

7. Debtors

	2025	2024
	£	£
Trade debtors	47,064	74,686
Other debtors	90,810	103,294
	---------	---------
	137,874	177,980
	---------	---------

The debtors above include the following amounts falling due after more than one year:

	2025	2024
	£	£
Other debtors	13,159	7,348
	--------	-------

8. Creditors: amounts falling due within one year

	2025	2024
	£	£
Bank loans and overdrafts	17,769	15,374
Trade creditors	122,698	146,201
Social security and other taxes	19,802	7,348
Other creditors	70,258	56,771
	---------	---------
	230,527	225,694
	---------	---------

Bank overdrafts are secured by an unlimited debenture over the assets of the company.

9. Creditors: amounts falling due after more than one year

	2025	2024
	£	£
Bank loans and overdrafts	2,977	12,761
Other creditors	4,805	16,091
	-------	--------
	7,782	28,852
	-------	--------

10. Called up share capital

Issued, called up and fully paid

	2025		2024
	No.	£	No.	£
Ordinary shares of £ 1 each	100	100	100	100
	----	----	----	----

11. Operating leases

The total future minimum lease payments under non-cancellable operating leases are as follows:

	2025	2024
	£	£
Not later than 1 year	28,231	4,260
Later than 1 year and not later than 5 years	90,772	5,445
	---------	-------
	119,003	9,705
	---------	-------

12. Director's advances, credits and guarantees

During the year the director had a loan from the company. The balance of the loan as at 30 November 2025 was £57,204 (2024: £56,326) and the maximum loan balance during the year was £57,204 (2024: £56,326). An amount of £1,817 (2024: £972) based on the official rate of interest-beneficial loan, was charged on this loan to the director, for interest.

		2025
		£
	Balance at 1 December 2024	56,326
	Other advances	47,378
	Amount repaid	(48,317)
		--------
		55,387
	Interest charged	1,817
		--------
	Balance at 30 November 2025	57,204
		--------

The above amount is repayable on demand.

13. Related party transactions

The company entered into the following related party transactions during the year:

Nature of Relationship	Transaction Type	2025	2024
		£	£
Director	Balance due to/(from)	(57,204)	(56,326)

Director	Rent received from the company	31,000	30,000
Other related party controlled by a director	Balance due to/(from)	40,255	24,262
Other related party controlled by a director	Balance due to/(from)	(324)	Nil

The director has provided a personal guarantee to Alliance Unichem Plc, which has provided guarantee to the company's banker.